ReviewMicrobial cell factories2015
Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes.
Review in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 147 citations in OpenAlex.
- Trial
- Protection against necrotic enteritis in broiler chickens by co-administration of Enterococcus faecalis EF32 and recombinant Lactobacillus plantarum strain co-expressing FimA, FimB, NetB and Fba.Poultry science · 2026Article
- Genetically Modified Lactic Acid Bacteria in the EU Food Chain: Applications, Benefits, and Risk Assessment.International journal of molecular sciences · 2026Review
- Genetically Modified Lactic Acid Bacteria: a Promising Mucosal Delivery Vector for Vaccines.Probiotics and antimicrobial proteins · 2026Review
- Development of a Mucosal Immune-Enhancing Oral Vaccine Candidate Against Porcine Epidemic Diarrhea Virus UsingAnimals : an open access journal from MDPI · 2026Article
- Lactic Acid Bacteria as the Green and Safe Food Preservatives: Their Mechanisms, Applications and Prospects.Foods (Basel, Switzerland) · 2026Review
- Article
- Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook.ACS applied bio materials · 2025Review
- Lactic acid bacteria as microbial cell factories for the in vivo delivery of therapeutic proteins as secretable TAT fusion products.Journal of biological engineering · 2025Article
- A new vaccination approach for Salmonellosis employing a multi-epitope vaccine based on live microbial cell factory from Lactococcus lactis.Poultry science · 2025Article
- Immunomodulatory Activity on Human Macrophages by Cell-Free Supernatants to Explore the Probiotic and Postbiotic Potential of Lactiplantibacillus plantarum Strains of Plant Origin.Probiotics and antimicrobial proteins · 2024Article
- Cytotoxic activity and apoptosis induction by supernatant ofIranian journal of microbiology · 2024Article
- A Novel Probiotic-Based Oral Vaccine against SARS-CoV-2 Omicron Variant B.1.1.529.International journal of molecular sciences · 2023Article
- Lactiplantibacillus plantarum: a new example of inclusion body producing bacteria.Microbial cell factories · 2023Article
- Effects of Fermented Food Consumption on Non-Communicable Diseases.Foods (Basel, Switzerland) · 2023Review
- Comparative Genomic Analysis Reveals the Functional Traits and Safety Status of Lactic Acid Bacteria Retrieved from Artisanal Cheeses and Raw Sheep Milk.Foods (Basel, Switzerland) · 2023Article
- Development of fluorescence-labeled antibody for immune checkpoint inhibitor using engineered probiotics.AMB Express · 2023Article
- How Long Will It Take to Launch an EffectiveInfection and drug resistance · 2023Review
- Expression of heterologous heparan sulphate binding protein of3 Biotech · 2023Article
- A novel, non-GMO surface display in Limosilactobacillus fermentum mediated by cell surface hydrolase without anchor motif.BMC microbiology · 2022Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactic acid bacteria (LAB) have a long history of safe exploitation by humans, being used for centuries in food production and preservation and as probiotic agents to promote human health. Interestingly, some species of these Gram-positive bacteria, which are generally recognized as safe organisms by the US Food and Drug Administration (FDA), are able to survive through the gastrointestinal tract (GIT), being capable to reach and colonize the intestine, where they play an important role. Besides, during the last decades, an important effort has been done for the development of tools to use LAB as microbial cell factories for the production of proteins of interest. Given the need to develop effective strategies for the delivery of prophylactic and therapeutic molecules, LAB have appeared as an appealing option for the oral, intranasal and vaginal delivery of such molecules. So far, these genetically modified organisms have been successfully used as vehicles for delivering functional proteins to mucosal tissues in the treatment of many different pathologies including GIT related pathologies, diabetes, cancer and viral infections, among others. Interestingly, the administration of such microorganisms would suppose a significant decrease in the production cost of the treatments agents since being live organisms, such vectors would be able to autonomously amplify and produce and deliver the protein of interest. In this context, this review aims to provide an overview of the use of LAB engineered as a promising alternative as well as a safety delivery platform of recombinant proteins for the treatment of a wide range of diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.